The INCA System: A Further Step Towards a Telemedical Artificial Pancreas by Gómez Aguilera, Enrique J. et al.
470 IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE, VOL. 12, NO. 4, JULY 2008
The INCA System: A Further Step Towards a
Telemedical Artificial Pancreas
Enrique J. Go´mez, Senior Member, IEEE, M. Elena Hernando Pe´rez, Member, IEEE, Thomas Vering,
Mercedes Rigla Cros, Oliver Bott, Gema Garcı´a-Sa´ez, Peter Pretschner, Eulalia Brugue´s, Oliver Schnell,
Caroline Patte, Joachim Bergmann, Ralf Dudde, and Alberto de Leiva
Abstract—Biomedical engineering research efforts have accom-
plished another level of a “technological solution” for diabetes:
an artificial pancreas to be used by patients and supervised by
healthcare professionals at any time and place. Reliability of
continuous glucose monitoring, availability of real-time pro-
grammable insulin pumps, and validation of safe and efficient
control algorithms are critical components for achieving that
goal. Nevertheless, the development and integration of these new
technologies within a telemedicine system can be the basis of
a future artificial pancreas. This paper introduces the concept,
design, and evaluation of the “intelligent control assistant for
diabetes, INCA” system. INCA is a personal digital assistant
(PDA)-based personal smart assistant to provide patients with
closed-loop control strategies (personal and remote loop), based on
a real-time continuous glucose sensor (Guardian RT, Medtronic),
an insulin pump (D-TRON, Disetronic Medical Systems), and a
mobile general packet radio service (GPRS)-based telemedicine
communication system. Patient therapeutic decision making is
supervised by doctors through a multiaccess telemedicine central
server that provides to diabetics and doctors a Web-based access
to continuous glucose monitoring and insulin infusion data. The
INCA system has been technically and clinically evaluated in two
randomized and crossover clinical trials showing an improvement
on glycaemic control of diabetic patients.
Index Terms—Artificial pancreas, diabetes, smart assistant,
telemedicine.
I. INTRODUCTION
D IABETES is a metabolic disorder primarily characterizedby elevated blood glucose levels and by microvascular
and cardiovascular complications that substantially increase the
morbidity and mortality associated with the disease, and reduce
the quality of life of diabetic patients. The cause of diabetes con-
tinues to be unknown, although both genetics and environmental
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factors appear to play important roles. At least 150 million peo-
ple today are diagnosed with diabetes, and by 2025, this number
is expected to rise to 300 million [1].
The vast majority of diabetes cases fall into broad etiopatho-
genetic categories: Type 1, Type 2, gestational diabetes, and
others. In Type 1 diabetes, the cause is an absolute deficiency
of insulin secretion. Nowadays, a well-treated Type 1 diabetic
patient can expect to have an almost normal life span as the
benefits of intensive therapy management have been well estab-
lished, and include reduced long-term complications [2]. Many
different technologies, methods, and approaches have been de-
veloped to improve the diagnosis, monitoring, and treatment of
diabetic patients such as biomedical sensors, as a basis for con-
tinuous blood glucose monitors; biomedical instrumentation, for
self-monitoring data collection and continuous insulin delivery;
mathematical modeling, for better understanding of the physio-
logical processes involved in the metabolic control [3]; and ap-
plication of information technologies, such as database manage-
ment systems, data analysis and visualization tools, intelligent
decision support techniques, and telemedicine systems. Com-
prehensive reviews on biomedical engineering technologies ap-
plied to diabetes management have been published [4], [5].
The combination of insulin pumps and continuous glucose
monitoring systems seems to be the best near future solution
to achieve a good metabolic control for insulin-treated diabetic
patients. A closed-loop device capable of maintaining normo-
glycaemia over extended periods of time could dramatically
improve the quality of metabolic control of insulin-treated di-
abetic patients [6]. Although the intravenous route is ideal for
control, the implementation of an ambulatory closed-loop sys-
tem imposes the use of the subcutaneous (SC) route as the
least invasive solution for insulin delivery and blood glucose
measurement. However, the glycaemic control based on the SC
route is complex because of the delayed exogenous insulin ab-
sorption and action during SC infusion and the delays due to
glucose monitoring systems. Several closed-loop control algo-
rithms for a subcutaneous infusion versus subcutaneous sensing
(SC–SC) setup have been reported [7], [8].
The dream of an “artificial pancreas” is starting to become
reality [9], [10], supported by the increased availability of
continuous glucose monitoring solutions, the integration of
control systems capable of closing the loop by modifying the
pump parameters, and the development of portable devices
with capabilities to manage the former technologies [11].
One of the most advanced solutions to achieve an SC–SC
closed-loop control system has been developed within the
1089-7771/$25.00 © 2008 IEEE
G ´OMEZ et al.: THE INCA SYSTEM: A FURTHER STEP TOWARDS A TELEMEDICAL ARTIFICIAL PANCREAS 471
research project “advanced insulin infusion using a control
loop” (ADICOL) [12] that developed a novel nonlinear model
predictive glucose controller, running on a portable hand-held
device to administer automatically a precise insulin dosage
using the information provided by the glucose sensor.
Telemedicine is providing innovative solutions in the effective
treatment of diabetic patients [13]–[15]. A telemedicine system
enhances the possibilities of traditional clinical procedures, pro-
viding both doctors and patients with an integrated service to
manage and improve daily diabetes care. Some of those benefits
are: 1) the increase of the quality and quantity of the information
collected by patients, affording a better decision-making process
for doctors and patients; 2) the improvement in the number of
therapy adjustments to be performed by doctors; 3) a better
physician–patient communication procedure; and 4) the impact
of the system to enhance the metabolic control of patients.
The number of telemedicine experiences for diabetes care has
significantly increased lately. Some of those experiences have
been focused on specific technological solutions for diabetes
management such as web-based systems [16] or multiaccess
services [17], while others are oriented toward aspects of the
illness such as depression [18] or diabetic retinopathy [19].
This paper presents a further step toward the artificial pan-
creas through the proof of concept of what we call a “telemedical
artificial pancreas.” The research has been performed by a re-
search consortium funded by the European Union (EU) project
“INCA–intelligent control assistant for diabetes.” The paper de-
scribes the INCA concept, the design of the mobile telemedicine
closed-loop architecture, and presents the preliminary clinical
evaluation results. Beyond that, a validated simulation for
the systematic analysis of the diabetes treatment workflow,
use-cases, and cost–benefit estimations has been accomplished.
II. INCA CONCEPT
The INCA telemedical artificial pancreas is built on two in-
terlinked loops (see Fig. 1): the personal loop that allows the
wireless communication between a PDA-based smart assistant
(SA), an insulin pump, and a continuous glucose measurement
device; and the remote loop that connects the diabetic patient
to the health care professional via his/her SA and its wireless
connection to a telemedicine central server (TMCS).
The INCA concept implies four control strategies; each of
them is supported by a special setup of the SA.
1) Patient control: The patient decides the changes in the in-
sulin pump programming by using the information com-
ing from a glucose sensor. The process is supervised
a posteriori by doctors based on the telemedicine services.
2) Doctor control: The health care professional suggests
changes in the insulin therapy using the continuous glu-
cose and insulin infusion information coming from the
personal SA through the TMCS.
3) Remote loop control algorithms: The SA is remotely pro-
grammed by automatic control procedures implemented
in the telemedicine server, under doctors’ supervision.
4) Personal loop control algorithms: The closed-loop al-
gorithms implemented in the SA provide a real-time
Fig. 1. INCA concept: Telemedical artificial pancreas.
control of the insulin pump based on glucose sensor
data.
The four control strategies allow coping with specific patient
preferences and requirements. The selection of a specific strat-
egy, or combination of strategies, will depend on the different
metabolic control situations of patients and also on the degree of
patient’s compliance. For example, an automatic personal loop
control algorithm could be active at night, and a patient or a
doctor control mode could be used during the day.
III. SYSTEM DESIGN AND SPECIFICATION
The design process of the INCA system is supported by a
user-centered and model-based design method. The resulting
concept and implementation of the personal loop, the remote
loop, and their interaction processes intensively make use of
current standards and a component-based approach to ensure
its sustainability.
A. MOSAIK-M INCA System Model
The analysis and design of the INCA system is based on
the previous experience of the research consortium [13], [15].
This knowledge and input from analysis and design phases
of the project have been formalized using modeling, simula-
tion, and animation of information and communication systems
in medicine (MOSAIK-M) [20]. In INCA, the MOSAIK-M
has been used for system analysis, system design, and cost–
benefit analysis. MOSAIK-M supports health information sys-
tems (HIS) analysis and design. It defines a generic process
scheme and a meta model, and includes a tool environment. The
generic process scheme guides modeling projects to produce
HIS models of high quality in terms of correctness, complete-
ness, and validity. The meta model defines the modeling lan-
guage, and thus, the components of MOSAIK-M models, i.e.,
organizational structures (especially technical and human ac-
tors), processes, object and information structures, and software
applications. MOSAIK-M models can be simulated and ani-
mated to support the analysis of HIS or user-oriented evaluation
of HIS. Physiological models are not subject of the MOSAIK-M
approach, but can be integrated in a MOSAIK-M model.
Two MOSAIK-M models have been created during the INCA
project: an “as is” and a “to be”-model. The “as is”-model
describes the current situation of a diabetic’s treatment with an
472 IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE, VOL. 12, NO. 4, JULY 2008
insulin pump, i.e., the problem domain. It identifies potential
users of the system, basic organizational structures, processes
and care-flows to support, and the definition and sources of
medical data. The “as is”-model has been verified concerning
its correctness and completeness due to the scope of the project
by experts of the application field (diabetologists and diabetics),
and was the starting point for generating a model of the INCA
telemedical system [20].
The resulting “to be” INCA-model includes a comprehensive
specification of the INCA system. It identifies 12 institutions and
37 roles of persons related to the INCA system; it describes 341
health care and technical processes that are directly or implicitly
affected by the INCA system, and defines 81 application object
classes and 358 application models. Thus, the “to be”-model is
a blue print for implementing and introducing the INCA sys-
tem into health care [20]. User interface prototypes are part
of the INCA-model, and were used for a formative evaluation
with diabetics, physicians, and technical partners prior to im-
plementing the system. Their integration into the simulation of
the system was further used to clear linguistic problems with
the interpretation of user interfaces, which was very important
in the international multilingual context of the project.
B. Specification of the Personal Loop
The SA mainly supports the personal loop and permits pa-
tients to perform the following tasks.
1) Management of monitoring data obtained from medical
devices (pump, blood glucose meter and continuous glu-
cose monitors) or directly from the patient (diet data and
additional events affecting blood glucose profiles such as
illness, menstruation, etc.).
2) Visualization of graphics and statistics of monitoring data.
3) Consultation of patient’s active therapy in terms of basal
profiles, bolus, and prescribed diet.
4) Virtual interface of the medical devices that allows pa-
tients to visualize and modify the configuration of their
devices and to download monitoring data from them.
5) Data communication with/to the TMCS: to exchange text
messages with the health care professionals (by current
mail applications installed in the PDA), to synchronize the
SA database, and to allow insulin pump remote control.
The other components that comprise the personal loop are the
insulin pump, the continuous glucose monitoring system, and
the blood glucose meter.
1) Insulin Pump: The insulin pump that was integrated into
the personal loop was based on a D-TRON (Disetronic Med-
ical Systems AG, Burgdorf, Switzerland). The pump is online
reprogrammed according to the basal profile defined at the SA
without the need of any manual operation on the pump.
The modified D-TRON insulin pump hardware is inherently
safe. In case of an error, it is always detected, signalized, and
handled, so that potentially hazardous situations can be pre-
vented. In the remote control mode via a cordless connection to
the PDA-based SA, the patient has to accept the insulin regime
change (basal insulin as well as insulin boli), before the pump
is reprogrammed.
2) Continuous Glucose Monitoring System: The original de-
sign of the SA is flexible in order to support the communication
to any glucose sensor system.
The prototype for monitoring continuous glucose uses a
microdialysis method with a bidirectional communication
between the SA and the sensor test system. The communication
protocol has been specified and implemented. However, the
current specifications of this glucose sensor for being used in
ambulatory environments prevented its use in clinical trials,
and it obliged to find an alternative solution for a real-time
continuous glucose monitoring.
The solution comes from an agreement with Medtronic-
Minimed to use the CGMS continuous glucose monitoring sys-
tem that gives the physician the retrospective information about
patient monitoring and the Medtronic-Minimed GuardianRT
system that provides patients with real-time glucose readings.
In both cases, continuous glucose profiles can be downloaded to
the TMCS to be remotely available for patients and physicians.
However, the bidirectional communication between the SA and
the Medtronic sensors have not been specified, and therefore,
neither implemented.
3) Glucose Meter: During the clinical trials, patients used
the Accu-Chek Sensor Complete Meter (Roche Diagnostics
GmbH, Germany) to measure blood glucose readings. The sys-
tem sends data to the telemedicine central server using a smart
modem. The user interface for data transmission is the glucose
meter and a modem activated with a unique button. Blood glu-
cose data is afterwards available at the SA personal logbook.
C. Specification of the Remote Loop
The remote loop is supported by the TMCS. This telemedicine
platform offers to both patients and physicians a tool for data
management and visualization, and supports the communication
with all user terminals.
The main Web features for patients are as follows: logbook
data management; graphical reports of blood glucose values,
continuous glucose monitoring data, and continuous insulin in-
fusion data (i.e., line charts, pie charts, and 24 h charts); view
therapy data; electronic health record management; messaging
tools to create, send and manage electronic mails and online
questionnaires; selecting and filling in questionnaires for tech-
nical, usable, and clinical evaluation of the system.
The main Web features for physicians are the following: Ther-
apy management for creating and editing therapy recommen-
dations; electronic health record management; view patient’s
logbook data; visualization of patient’s monitoring data (blood
glucose values, insulin values, diet, ketonuria, stress, illness,
etc.); graphical reports of blood glucose values, continuous glu-
cose monitoring data, and continuous insulin infusion data; mes-
saging tools to create, send, and manage electronic mails; and
follow-up of the questionnaires filled in by patients.
D. Remote and Personal Loop Interaction Process Modeling
In this section, we describe the interaction diagrams between
INCA users and main components of the personal and remote
loop systems. Fig. 2 presents an example of the sequence of
actions within the personal loop.
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Fig. 2. Personal loop interaction diagram (TMCS: telemedicine central
server).
The patient uses the SA as a personal logbook for disease self-
management, data monitoring analysis, communication with the
medical devices, manual data entry, and consultation of current
therapy proposed by physicians.
The SA pump virtual interface (PVI) allows for gathering
information about the current pump programming and the in-
sulin delivered over time (insulin basal rates and bolus). The
PVI scenario enables patients to control the pump. New basal
rates and current pump configuration, such as date and time, can
be changed. After any programming operation, a confirmation
is received in the PVI. For the closed-loop control, the SA is
equipped with a control algorithm [12] that calculates insulin
infusion rates upon patient’s request.
The patient initiates a synchronization process to update per-
sonal monitoring data to the hospital or to download therapy
changes recommended by the physician and other data stored at
the server. This procedure sends the data stored in the SA to the
INCA TMCS or retrieve new data from the TCMS to the SA.
Fig. 3 shows the interaction diagram of the remote loop pro-
cess to support the physician decision process. The physician
monitors the patient’s metabolic state through the interaction
with the TMCS Web application. He/she can propose a change
in the insulin therapy that is notified to the patient, and is later
on downloaded into the SA.
The physician could also directly manage the patient insulin
pump through the pump remote control. The process involves
a real-time notification to the SA that will be received by the
patient. After an explicit patient consent, the SA reprograms the
current insulin profiles in the pump.
IV. INCA SMART ASSISTANT
A. General Description
The INCA SA communicates with the patient devices through
a personal wireless network (local loop) and additionally
Fig. 3. Remote loop interaction diagram (SA: smart assistant; TMCS:
telemedicine central server).
Fig. 4. SA software modules.
through a mobile wide area network (WAN) for providing tele-
monitoring, telecare, and remote information services (remote
loop). The user terminal that supports the SA is a commer-
cial PDA provided with wireless communication facilities, such
as infrared, Bluetooth, and mobile GPRS. The SA works as
a stand-alone system, supported on its own local application
and database. The use of always-on networks such as the mo-
bile GPRS, allows for a periodic update of the SA data from
the medical devices and transfer new data to the INCA central
server. The communication can be activated upon user’s request.
B. Smart Assistant Architecture
The SA architecture consists of several software modules as
shown in Fig. 4.
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Fig. 5. Example of the SA user interface. (a) Pump virtual interface. (b)
Graphic representation of blood glucose readings.
1) User Interface Module: The SA user interface supports
multilanguage features, and was used in English, Spanish, Cata-
lan, and German versions. The interface implementation is based
on the Java Abstract Windows Toolkit (AWT), and offers a high
scalability to the application.
Several submodules can be distinguished: the “DeviceMan-
ager” module provides a high-level vendor-independent inter-
face for common procedures of reading and programming events
on medical devices [see Fig. 5(a)]; the “User Information” mod-
ule allows introducing personal data and the required password
to access the database interchange process; the “Self Monitor-
ingData” module allows data visualization in the patient log-
book, and makes possible the introduction of new monitoring
data and changes in previously entered data [see Fig. 5(b)]; the
“Therapy” module allows the visualization of current insulin
and diet treatment; The “SA_Settings” module sets user prefer-
ences, and registers changes in personal data.
2) Data Access Module: The Data_Access module provides
all the other modules with the access to the SA local database
using a Java Database Connectivity (JDBC) interface, both for
data retrieval, modification and insertion.
3) Comm_Devices Module: The Comm_Devices manages
the communications with the medical devices in the personal
loop (the continuous glucose monitor, the glucose strip meter,
and the insulin pump), supported via serial ports, infrared, and/or
Bluetooth.
4) Model Predictive Control (MPC) Module: The MPC
module implements the closed-loop model predictive control
developed within the ADICOL experience [12]. The control al-
gorithm is based on the physiologic model described by Hovorka
et al. [21]. The MPC calculates changes in the insulin delivered
by the pump based on results from the continuous glucose mea-
surement. The algorithm can also provide insulin bolus advice
before each meal intake. Using this algorithm within the SA im-
plies extracting continuous monitoring data stored in the local
database following the structure imposed by the MPC model.
5) Telemedicine Central Server Module: The TMCS module
manages the interaction between the TMCS and the SA for
data exchange as well as for the remote control of the medical
devices. It requires an active mobile GPRS connection. The
remote control procedures are supported on Common Object
Request Broker Architecture (CORBA), which allows the SA
to behave as an always on server. The SA receives external
remote control requests via mobile GPRS [22].
C. Hardware and Software Platform
The SA hardware platform is an iPAQ hp2210 PDA that inte-
grates Bluetooth for wireless communication, and it is provided
with the AudioVox RTM 8000 for mobile GPRS communication
capabilities. The software application is developed in a Java pro-
gramming language using the Java Development Kit 1.1.8. and
the CrEme v3.24 JVM that provides packages such as JDBC,
CORBA, and RMI.
V. TELEMEDICINE CENTRAL SERVER
A. Telemedicine Architecture
The architecture of the TMCS is based on a telemedicine mul-
tiaccess server (MAS) [23] that allows users to access the infor-
mation, using any access terminal or combination of terminals
they choose. The new features and software agents integrated
in the architecture support the integration of the new devices
and data considered in the INCA system: insulin pump, SA, and
continuous glucose monitor.
A concept and a prototype system have been developed for the
integration of the TMCS into a comprehensive regional health
information infrastructure (RHII). The INCA diabetes docu-
mentation thus becomes a part of the patient’s virtual shared
health record. The INCA database is mounted with a connec-
tor/mediator module into the RHII, allowing authorized care
providers to access: 1) information of the diabetes logbook
and 2) the clinical diabetes documentation like laboratory re-
sults and findings. The information of the various interorgani-
zational data sources is linked with unique patient identifiers
stored on patient cards. For authorization purposes, a patient is-
sues electronic tickets (so-called e-consents) to care providers.
These e-consents are digitally signed certificates, authorizing
the respective health professional for access to the shared health
record for a limited time with individually parameterized ac-
cess rights. Semantic interoperability is achieved by using the
clinical document architecture (CDA) [24].
B. Web-Based User Interface
The starting point of the Web user interface was an existing
telemedicine system [13], [15], [23] that has been modified
to support the continuous monitoring data for diabetes control
considered in the INCA system.
Fig. 6 shows an example of the Web-based user interface to
allow patients and doctors to access through the Web to the
continuous glucose monitoring and continuous insulin infusion
data, enhancement of integrated data presentation, and printing
of patient logbook.
VI. EVALUATION OF THE INCA SYSTEM
The four control strategies of the INCA concept have been
technically evaluated in the laboratory with prototype devices,
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Fig. 6. Example of INCA Web-based user interface: patient report showing
continuous glucose monitoring and continuous insulin infusion data.
but the clinical evaluation of strategies #3 and #4 is still unfin-
ished due to the difficulty of using sensors and insulin pumps
with real-time reading and programming in clinical pilots.
Up to date, we performed three clinical experiments [26],
[27], and their results provided useful information about dif-
ficulties in the use of the SA technology and the impact of
continuous glucose monitoring on patients’ metabolic control.
The system evaluation assesses the performance according
to technical implementation, user satisfaction, clinical utility,
clinical efficacy and effectiveness, and quality of care. The eval-
uation has been conceived as a subjective evaluation, based
on users’ questionnaires, and an objective evaluation based on
clinical data registered by health care professionals and the au-
tomatic tracking of user’s interactions with the Web or PDA to
obtain information about the use of the system.
A. Feasibility Pilot
Objective: To assess the technical feasibility of the INCA
system. Clinical evaluation was not done at this stage.
Methods: During six months, a group of four Type 1 pump-
treated diabetic patients from the Institut fu¨r Diabetesforschung
(Munich, Germany) evaluated the technical components of the
system using the control strategies #1 and #2.
Results: The pattern of system usage varies between individ-
uals, but all of them registered and sent data to the hospital on
a regular basis. Main technical difficulties came from the mo-
bile GPRS communication and the use of the PDA: 1) GPRS
connection failed when very high amounts of data were trans-
mitted (e.g., data from several months); 2) the limited GPRS
connection coverage in some suburban areas; and 3) PDA bat-
tery consumption during data transmission.
Conclusions: The use of the SA is feasible in ambulatory
scenarios.
B. Clinical Trial 1
Objective: To evaluate the clinical utility of the INCA control
strategies #1 and #2 based on BG self- monitoring and continu-
ous insulin monitoring.
Methods: Ten Type 1 pump-treated diabetic patients from
Hospital de Sant Pau (Barcelona, Spain) participated in a ran-
domized crossover study (four weeks + four weeks). Patients
were recruited from those regularly attended in the outpatients’
diabetic clinics of the Hospital de Sant Pau, a tertiary hospital
with a reference population of about 400 000 people. After ran-
domization, patients were allocated in one of the two groups:
control or intervention. During the control phase, patients did
not receive any feedback from the medical center, but they had
to send glucose data for a retrospective analysis. During the in-
tervention phase, patients were able to use both the SA and all
the telemedicine services. Data sent by patients were analyzed
by the physician, and modifications of the basal rates and boli
were advised in the following 24 h. Within the last week of
each period, the patients used a three-day subcutaneous blind
glucose monitoring (Medtronic-Minimed CGMS) for a retro-
spective evaluation between periods. Fructosamine and HbA1c
were registered at the start and end of each period. Question-
naires and system data were used to assess the user satisfaction
and system usage.
Results: After the experimental phase, fructosamine de-
creased significantly (393 ±32 versus 366 ±25 umol/L; p <
0.05) and HbA1c tended to decrease (8.0 ±0.6 versus 7.78
±0.6; p = 0.073), while no changes were observed during the
control phase [26]. In terms of system utility, all the patients
stated that the INCA system helped them to communicate with
the physician in an effective way and increased the flexibility
of therapy management. All the patients stated that the use of
the system makes them feel more secure in the handling of di-
abetes, and six out of ten patients considered that the system
helped them to reduce the number of acute problems related
to their diabetes (hypoglycaemias, ketosis, etc.). Patients would
recommend the INCA system for diabetes care (78% in total
agreement and 22% in partial agreement), and considered that
it is easy to learn how to use it, and it helped them to understand
and analyze their monitoring data quickly and more effectively.
Conclusions: The usage of the wireless SA for remote treat-
ment advising allows better glycaemic control in pump-treated
Type 1 diabetic patients. Patients’ satisfaction was very high.
C. Clinical Trial 2
Objective: To evaluate the clinical utility of the INCA control
strategies #1 and #2 based on continuous insulin monitoring and
real-time continuous glucose monitoring versus the same INCA
usage and capillary BG self-monitoring.
Methods: The ten Type 1 pump-treated diabetic patients from
Hospital de Sant Pau (Barcelona, Spain) participated in a ran-
domized crossover study (four weeks + four weeks) [27]. The
design of the control phase was similar to the intervention phase
in clinical trial 1. In the intervention phase, patients addition-
ally wore the continuous glucose sensor Guardian (Medtronic
MiniMed, Northridge, CA), three days per week.
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Results: The usage and usability evaluation results did not
show many differences in comparison to the clinical trial 1. Af-
ter the intervention phase, HbA1c decreased in nine out of ten
patients, the mean decrease being 0.8% (p = 0.007). No change
was observed during the control phase. Although HbA1c im-
proved significantly, the percentage of glucose readings below
70 did not increase. Furthermore, patients did not suffer from
any severe hypoglycaemia along the study.
Conclusions: The experiment demonstrated that patients
achieved a better metabolic control when using real-time glu-
cose monitoring enhanced with the INCA control strategies #1
and #2.
D. Cost–Benefit Analysis
Cost–benefit analyses of systems like INCA are needed to pre-
pare the decision on their introduction for routine care. To con-
duct a cost analysis on the example of Germany, the MOSAIK-
M “as is”-model and the “to be”-model were parameterized with
cost values from the German KoDiM study, and a period of one
year was simulated to determine the yearly costs of diabetes
management and treatment for a patient who does not suffer
from diabetes-related complications yet [28]. The HbA1c-value
was chosen as an effectiveness parameter for diabetes therapy.
To determine the probability of developing complications and
their probable duration, the Archimedes model [29] was used. It
was parameterized with selected HbA1c-values anticipating the
effect of INCA, respectively, from the trials. The yearly costs
of conventional insulin pump treatment for a 19-year-old dia-
betes Type 1 patient with no complications are 5907 € (German
health care system; September 2005). Using the INCA system
with continuous blood glucose measurement of 24 h a day and
seven days a week would raise the yearly costs by 7348 €.
The cost efficiency of the INCA approach highly depends
on the cost of the continuous blood glucose measurement. Fur-
ther work is needed to complete the cost–benefit analysis by
including calculating monetary effects on treatment costs due
to a reduced HbA1c-value as determined by the clinical studies,
and indirect (e.g., loss of working hours) and intangible (e.g.,
reduction of quality of life) costs.
VII. DISCUSSION
The enormous biomedical engineering efforts performed over
the last three decades still leave room for improvement in order
to achieve a “technological solution” for diabetes: an artificial
pancreas system to be used by diabetic patients at any time
and place. This challenge implies new research work to face
yet unsolved difficulties: 1) insulin pumps that allow real-time
insulin infusion programming are not commercially available;
2) the need of a reliable and cost-efficient continuous glucose
monitoring technology; 3) the development and clinical valida-
tion of safe and efficient closed-loop control algorithms, coping
with the inherent complexity of an SC–SC setup in ambulatory
environments; and 4) the integration of these new technologies
and therapeutic procedures within a telemedicine system that
provides patients and doctors a safe, convenient, and efficient
tool in a day-by-day normal life.
The INCA concept has defined four closed-loop control
strategies in which the decision-making process moves from
the physician to the patient and from the patient to an automatic
decision-support system. The INCA technology is ready for im-
plementing in clinical routine to all these approaches. However,
the current stage of glucose sensing and insulin infusion tech-
nologies allowed the clinical evaluation of the first and second
control strategies in which a complete automatic telemedical
closed-loop solution is not considered.
The use of insulin pumps in an artificial pancreas requires a
periodic and automatic adjustment of the insulin dosage depend-
ing on the glycaemic values. In order to do this, a real-time pro-
grammable pump must be utilized. In order to demonstrate the
technical feasibility, we used a modified insulin pump provided
by the partner Disetronic Medical Systems AG. This modified
pump is remotely controllable (basal insulin as well as insulin
boli) within the INCA system via a cordless connection to the
PDA-based SA. History data can be downloaded from the pump
via Bluetooth and infrared communication to the SA, which af-
terwards can be transmitted to the TMSC.
Another requirement for implementing a telemedical artificial
pancreas is the acquisition of glucose measurements with min-
imum delays in real time. Several technologies and approaches
have been applied to implement real-time continuous glucose
sensors. The most widely investigated type of glucose sensor
is the amperometric enzyme electrode implanted in the SC tis-
sue [4] such as the Guardian RT (Medtronic) that shows glucose
data in real time every 5 min. Other companies such as DexCom
and Abbott follow the same technological approach for their am-
perometric needle-type sensors. However, some inherent prob-
lems of this technology are the insufficient signal stability of
the glucose electrodes and the accuracy limitations in situations
of hypoglycaemia and hyperglycaemia. Microdialysis as used
in the Menarini system, although frequently related with tech-
nical signal delays, generally avoids undesirable sensor–tissue
interactions.
The SA has been designed in a flexible way so that differ-
ent sensor systems can be supported and practically used. Due
to its high robustness, our first choice was therefore to use a
microdialysis-based system with the Sa. A prototype of such a
sensor provided real time glucose data to the SA that was entered
into a closed-loop control algorithm [12] that was also imple-
mented in the SA. Laboratory and technical feasibility tests of
the personal loop were done with this sensor. However, the lack
of suitable microdialysis sensor systems to be used in ambu-
latory settings did not allow any testing in the clinical trials.
In order to implement the INCA SA in a telemedical clinical
setting, we decided to employ the Guardian RT (Medtronic).
This sensor was integrated in the telemedicine applications and
allowed us to leverage the benefits of continuous glucose mon-
itoring and telemedicine, but the sensor did not permit to test
the MPC closed-loop algorithm because sensor data could not
be downloaded in real time to the SA. Current research focuses
on integrating the new sensor devices in the SA architecture.
The INCA architecture has been designed to follow the ex-
pected rapid evolution of mobile technologies as all the long-
distance communications assume the availability of any IP
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network that are also available in the new mobile 3G networks.
However, this standardized scenario is not so mature in the per-
sonal area network where medical devices have to be connected
and operated. The main issue is that communications with in-
sulin pumps, continuous glucose sensors, and glucometers are
not standardized at all and the integration of any new device into
the SA will require new developments and the collaboration of
manufactures to replicate the communication protocols.
Telemedicine has demonstrated its efficiency to decrease
HbA1c of patients [13], [1], and the research presented here
extends the good outcomes of telecare together with the con-
tinuous glucose monitoring to achieve the artificial pancreas in
real-life settings.
VIII. CONCLUSION
The concept and realization of a mobile telemedicine closed-
loop system for diabetes management has been presented in
this paper. The INCA system implemented for the first time a
PDA-based SA for patients that manage a continuous glucose
sensor and an insulin pump, integrated in a telemedicine system
that offers to diabetic patients and doctors a Web-based access
for continuous glucose monitoring and continuous insulin in-
fusion data. The results of the clinical trials show the technical
feasibility of the telemedical artificial pancreas concept and the
clinical benefits of the use of continuous glucose monitoring
system within a personal assistant, integrated in a telemedicine
system, to better the HbA1c of patients. The ultimate goal of
this research is to build a telemedical artificial pancreas toward
looking for new technological solutions to improve the quality
of care and quality of life of people with diabetes.
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